Tuberculosis and renal transplantation—observations from an endemic area of tuberculosis

Malhotra, K. K.; Dash, Suvashis; Dhawan, I. K.; Bhuyan, U N; Gupta, Anju

doi:10.1136/pgmj.62.727.359

Cited by 59 publications

(26 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We recorded no mortality among patients with post transplant tuberculosis. This is in accordance with other studies, which have also noted no or very low mortality among cases with post transplant pulmonary tuberculosis [7,22]. Jha R [1] et al found M. tuberculosis in 10 out of the 27 pulmonary infections among 142 patients of which 2 resulted in mortality but the cause of death was attributed to delay in treatment.…”

Section: Discussionsupporting

confidence: 91%

“…This incidence is higher than that noted by Agarwal et al [20] who found that pulmonary tuberculosis recurred in only one patient out of the eight with pre transplant tuberculosis and by Malhotra et al [22] who also noted a recurrence in only 1 out of 11 patients. None of the patients in our study who developed tuberculosis had received prophylaxis against tuberculosis.…”

Section: Discussioncontrasting

confidence: 57%

See 1 more Smart Citation

Spectrum of Pulmonary Infections in Renal Transplant Recipients in the Tropics: A Single Center Study

et al. 2005

View full text Add to dashboard Cite

Our study has shown that more than 1/3rd of pulmonary infections in renal transplant recipients can be attributed to multiple organisms. Bacterial infections were the commonest cause of post transplant pulmonary infection. Tuberculosis is common cause of pulmonary infection in these patients in our set up. Because of its high diagnostic yield, BAL should be considered in all patients with suspected pulmonary infections in the post transplant period.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussioncontrasting

confidence: 57%

Spectrum of Pulmonary Infections in Renal Transplant Recipients in the Tropics: A Single Center Study

et al. 2005

View full text Add to dashboard Cite

show abstract

“…[3][4][5][6] In developed countries where population rates of active tuberculosis are low (less than 20 per 100 000), only 0.26% to 6.5% of transplant recipients develop tuberculosis. [7][8][9] Tuberculosis continued to be a major problem as recently as 2007 even in a large transplant center in New York, where they reported an incidence 10-30 times higher than general population during the same period in the same location.…”

Section: Discussionmentioning

confidence: 99%

Mycobacterium Tuberculosis in Solid Organ Transplantation: Incidence before and after Expanded Isoniazid Prophylaxis

Al-Mukhaini¹,

Aleid²,

Alduraibi³

et al. 2017

Ann Saudi Med

View full text Add to dashboard Cite

“…The incidence of post-transplantation TB [4] is reported to be 0.35-1.2% in the United States, 0.7-5% in Europe, 1.5-3.5% in the Middle East, 5-15% in Pakistan [5] and India [6][7][8][9][10][11][12][13]. Although systemic manifestations are typically severe, there is increase in frequency of extra pulmonary TB, disseminated TB and presentation as fever of unknown origin in this group of patients.…”

Section: Introductionmentioning

confidence: 99%

Prospective randomised trial of isoniazid prophylaxis in renal transplant recipient

et al. 2004

Self Cite

View full text Add to dashboard Cite

Renal transplantation (RT) recipients are at a high risk of developing tuberculosis (TB) following transplantation. Effectiveness of isoniazid (INH) in preventing TB is well documented in immunocompetent as well as immunocompromised persons. There is paucity of data on role of INH prophylaxis in RT recipients. Thus, a prospective randomised trial of INH in RT recipients was carried out to determine the efficacy of daily INH monotherapy in the prevention of TB in these patients. Patients of end stage renal disease (ESRD) taken for RT formed the subjects of study. Patients with active TB and active hepatitis at the time of RT were excluded from the study. Patients were randomised to receive INH 300 mg with pyridoxine 20 mg daily from the day of RT. The duration of the treatment was planned for 1 year or till the development of TB, which ever was earlier. Between October 1998 and September 2000, 114 RT were done at our hospital. Of these, 24 (21%) patients had active TB at the time of RT and thus were excluded. Patients included were randomised with 1:2 ratio of treatment and control group. Of the 90 patients thus enrolled, 30 were randomised in treatment group and 60 in control group. Of the included patients five patients had very early graft loss (three in treatment and two in control group) within days and thus excluded from the analysis. Three of the 27 (11.1%) patients in treatment group and 15 (25.8%) in control group developed TB (P = 0.10). The risk ratio of (RR) of INH versus control group of TB was 0.36 (95% CI, 0.10-1.32) but the difference was not statistically significant (P = 0.12). Only one patient developed INH induced hepatitis. In conclusion, with INH prophylaxis, there was a trend towards protection from TB, though it was not statistically significant. Further, all patients tolerated INH and hepatotoxicity was not a major problem in this group of patients.

show abstract

Tuberculosis and renal transplantation—observations from an endemic area of tuberculosis

Cited by 59 publications

References 11 publications

Spectrum of Pulmonary Infections in Renal Transplant Recipients in the Tropics: A Single Center Study

Spectrum of Pulmonary Infections in Renal Transplant Recipients in the Tropics: A Single Center Study

Mycobacterium Tuberculosis in Solid Organ Transplantation: Incidence before and after Expanded Isoniazid Prophylaxis

Prospective randomised trial of isoniazid prophylaxis in renal transplant recipient

Contact Info

Product

Resources

About